Serotonergic 5-HT6 Receptor Antagonists: Heterocyclic Chemistry and Potential Therapeutic Significance

被引:19
作者
Bali, Alka [1 ]
Singh, Shalu [1 ]
机构
[1] Panjab Univ, UGC Ctr Adv Study, Univ Inst Pharmaceut Sci, Chandigarh 160014, India
关键词
5-HT6; antagonists; Alzheimer's disease; Antiobesity agents; Cognition enhancers; Indole derivatives; Memory; Schizophrenia; ALZHEIMERS-DISEASE; DOUBLE-BLIND; PHARMACOLOGICAL CHARACTERIZATION; COGNITIVE DYSFUNCTION; HIGH-AFFINITY; WATER MAZE; SCHIZOPHRENIA; RAT; BINDING; DERIVATIVES;
D O I
10.2174/1568026615666150427110420
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The serotonin 5-HT6 receptor (5-HT6R) is amongst the recently discovered serotonergic receptors with almost exclusive localization in the brain. Hence, this receptor is fast emerging as a promising target for cognition enhancement in central nervous system (CNS) diseases such as Alzheimer's disease (cognitive function), obesity, schizophrenia and anxiety. The last decade has seen a surge of literature reports on the functional role of this receptor in learning and memory processes and investigations related to the chemistry and pharmacology of 5-HT6 receptor ligands, especially 5-HT6 receptor antagonists. Studies show the involvement of multiple neurotransmitter systems in cognitive enhancement by 5-HT6R antagonists including cholinergic, glutamatergic, and GABAergic systems. Several of the 5-HT6R ligands are indole based agents bearing structural similarity to the endogenous neurotransmitter serotonin. Based on the pharmacophoric models proposed for these agents, drug designing has been carried out incorporating various heterocyclic replacements for the indole nucleus. In this review, we have broadly summarized the medicinal chemistry and current status of this fairly recent class of drugs along with their potential therapeutic applications.
引用
收藏
页码:1643 / 1662
页数:20
相关论文
共 169 条
[1]   Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists [J].
Ahmed, M ;
Briggs, MA ;
Bromidge, SM ;
Buck, T ;
Campbell, L ;
Deeks, NJ ;
Garner, A ;
Gordon, L ;
Hamprecht, DW ;
Holland, V ;
Johnson, CN ;
Medhurst, AD ;
Mitchell, DJ ;
Moss, SF ;
Powles, J ;
Seal, JT ;
Stean, TO ;
Stemp, G ;
Thompson, M ;
Trail, B ;
Upton, N ;
Winborn, K ;
Witty, DR .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4867-4871
[2]  
Ahmed M., 2003, Patent No. [2003080580, 2003080580A2]
[3]   A review on cholinesterase inhibitors for Alzheimer's disease [J].
Anand, Preet ;
Singh, Baldev .
ARCHIVES OF PHARMACAL RESEARCH, 2013, 36 (04) :375-399
[4]  
[Anonymous], PHARM LIBR
[5]  
[Anonymous], [No title captured], Patent No. 941994
[6]   Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats [J].
Arnt, Jorn ;
Bang-Andersen, Benny ;
Grayson, Ben ;
Bymaster, Franklin P. ;
Cohen, Michael P. ;
DeLapp, Neil W. ;
Giethlen, Bruno ;
Kreilgaard, Mads ;
McKinzie, David L. ;
Neill, Joanna C. ;
Nelson, David L. ;
Nielsen, Soren M. ;
Poulsen, Mette N. ;
Schaus, John M. ;
Witten, Louise M. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (08) :1021-1033
[7]  
Becker O., 2006, Preparation of Piperazinylarylamines as 5-HT6 Modulators, Patent No. [WO/2006081332, 2006081332]
[8]   Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease [J].
Benhamu, Bellinda ;
Martin-Fontecha, Mar ;
Vazquez-Villa, Henar ;
Pardo, Leonardo ;
Lopez-Rodriguez, Maria L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (17) :7160-7181
[9]  
Bentley J., 1997, J Psychopharmacol, V11, pA64
[10]   Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats [J].
Bentley, JC ;
Bourson, A ;
Boess, FG ;
Fone, KCF ;
Marsden, CA ;
Petit, N ;
Sleight, AJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (07) :1537-1542